Crizotinib in ALK-positive lung cancer

被引：4
|
作者：
Girard, Nicolas [1 ]
机构：
[1] Louis Pradel Hosp, F-69500 Bron, France
来源：
LANCET ONCOLOGY | 2012年 / 13卷 / 10期
关键词：
ANAPLASTIC LYMPHOMA; CELL; KINASE;
D O I：
10.1016/S1470-2045(12)70375-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：962 / 963
页数：2
相关论文
共 50 条
  • [41] Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer
    Ruano-Ravina, Alberto
    Provencio-Pulla, Mariano
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S54 - S56
  • [42] Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer
    Yoshida, Tatsuya
    Oya, Yuko
    Tanaka, Kosuke
    Shimizu, Junichi
    Horio, Yoshitsugu
    Kuroda, Hiroaki
    Sakao, Yukinori
    Hida, Toyoaki
    Yatabe, Yasushi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (28) : 3383 - +
  • [43] Alectinib in crizotinib-resistant, ALK-positive NSCLC
    Jassem, Jacek
    LANCET ONCOLOGY, 2016, 17 (02): : 134 - 135
  • [44] Ceritinib versus chemotherapy in ALK-positive lung cancer
    Marshall, Hilary
    LANCET RESPIRATORY MEDICINE, 2016, 4 (12): : 952 - 953
  • [45] Esophagitis A Novel Adverse Event of Crizotinib in a Patient with ALK-Positive Non-Small-Cell Lung Cancer
    Srivastava, Neeharika
    VanderLaan, Paul A.
    Kelly, Ciaran P.
    Costa, Daniel B.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : E23 - E24
  • [46] Regarding the prognostic factors in patients with ALK-positive non-small cell lung cancer treated with crizotinib
    Hu, Limei
    Xie, Youjun
    Zhao, Hongying
    PULMONOLOGY, 2024, 30 (04): : 406 - 407
  • [47] Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
    Nishio, Makoto
    Kim, Dong-Wan
    Wu, Yi-Long
    Nakagawa, Kazuhiko
    Solomon, Benjamin J.
    Shaw, Alice T.
    Hashigaki, Satoshi
    Ohki, Emiko
    Usari, Tiziana
    Paolini, Jolanda
    Polli, Anna
    Wilner, Keith D.
    Mok, Tony
    CANCER RESEARCH AND TREATMENT, 2018, 50 (03): : 691 - 700
  • [48] Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer
    Kang, Jin
    Chen, Hua-Jun
    Zhang, Xu-Chao
    Su, Jian
    Zhou, Qing
    Tu, Hai-Yan
    Wang, Zhen
    Wang, Bin-Chao
    Zhong, Wen-Zhao
    Yang, Xue-Ning
    Chen, Zhi-Hong
    Ding, Yan
    Wu, Xue
    Wang, Mei
    Fu, Jian-Gang
    Yang, Zhenfan
    Zhang, Xian
    Shao, Yang W.
    Wu, Yi-Long
    Yang, Jin-Ji
    THORACIC CANCER, 2018, 9 (09) : 1093 - 1103
  • [49] Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer
    Yoshida, Tatsuya
    Oya, Yuko
    Tanaka, Kosuke
    Shimizu, Junichi
    Horio, Yoshitsugu
    Kuroda, Hiroaki
    Sakao, Yukinori
    Hida, Toyoaki
    Yatabe, Yasushi
    LUNG CANCER, 2016, 97 : 43 - 47
  • [50] Better Clinical Outcomes and Resistance Mechanisms of Crizotinib in ALK-Positive Non-Small Cell Lung Cancer
    Zhang, Y.
    Liang, Z.
    Li, Y.
    Yang, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S1003 - S1003
12345